Immunogenic potential of three transmissible venereal tumor cell lysates to prime canine-dendritic cells for cancer immunotherapy
- PMID: 30316013
- DOI: 10.1016/j.rvsc.2018.10.001
Immunogenic potential of three transmissible venereal tumor cell lysates to prime canine-dendritic cells for cancer immunotherapy
Abstract
Whole tumor cell lysates consist of a mixture of tumor antigens and danger associated molecular patterns (DAMPs) that can be used for dendritic cell maturation and consequently for the activation of a polyclonal T cell-specific tumor response. We evaluated the in vitro efficacy of three different preparations of canine transmissible venereal tumor (TVT) cell lysates: hypochlorous acid-whole tumor cell lysates (HOCl-L), heat shock-whole tumor cell lysates (HS-L), and freeze-thaw cycles-whole tumor cell lysates (FT-L) for the maturation of canine-derived dendritic cells. Our results showed calreticulin, HSP70, and HSP90 release in the three tumor lysates preparations (HOCl-L, HS-L, and FT-L); however, HMGB1 was detected only in HOCl-L and FT-L. Additionally, the uptake by HOCl-L pulsed dendritic cell (DC) increased compared to HS-L and FT-L pulsed DC; and dendritic cell maturation was confirmed by the appropriate cell surface markers (CD11c, CD80, CD83, and MHCII). Furthermore, dendritic cells pulsed with HOCl-L, HS-L or FT-L were cultured with canine lymphocytes. There was an increase of Th1-type cytokines (IL-12, TNF-α, and IFN-γ), in all the tumor cell lysates co-cultures, this correlates with T lymphocyte activation and cytotoxic response. Our data confirm that TVT cell lysates can induce functional canine-DC and that HOCl-L is the most effective one. This preparation of TVT cell lysates with HOCl is an attractive approach that allows the recognition of neoantigens as potential tumor targets and DC priming and therefore could be used for cancer immunotherapy against TVT.
Keywords: Cancer; Dendritic cells; Immunotherapy; Transmissible venereal tumor; Tumor cell lysate.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Immunotherapy for the treatment of canine transmissible venereal tumor based in dendritic cells pulsed with tumoral exosomes.Immunopharmacol Immunotoxicol. 2019 Feb;41(1):48-54. doi: 10.1080/08923973.2018.1533969. Epub 2018 Dec 20. Immunopharmacol Immunotoxicol. 2019. PMID: 30334465
-
Tumor cell lysates as immunogenic sources for cancer vaccine design.Hum Vaccin Immunother. 2014;10(11):3261-9. doi: 10.4161/21645515.2014.982996. Hum Vaccin Immunother. 2014. PMID: 25625929 Free PMC article. Review.
-
Autologous canine immunotherapy: short-time generated dendritic cells loaded with canine transmissible venereal tumor-whole lysate.Immunopharmacol Immunotoxicol. 2018 Oct;40(5):437-443. doi: 10.1080/08923973.2018.1523928. Epub 2018 Dec 3. Immunopharmacol Immunotoxicol. 2018. PMID: 30507311
-
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9. Clin Cancer Res. 2013. PMID: 23838316 Free PMC article.
-
Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer.Cancer Immunol Immunother. 2018 Dec;67(12):1897-1910. doi: 10.1007/s00262-018-2157-5. Epub 2018 Mar 29. Cancer Immunol Immunother. 2018. PMID: 29600445 Free PMC article. Review.
Cited by
-
Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell.Adv Sci (Weinh). 2023 Aug;10(22):e2300121. doi: 10.1002/advs.202300121. Epub 2023 May 31. Adv Sci (Weinh). 2023. PMID: 37254712 Free PMC article. Review.
-
Plasma-Activated Medium Potentiates the Immunogenicity of Tumor Cell Lysates for Dendritic Cell-Based Cancer Vaccines.Cancers (Basel). 2021 Apr 1;13(7):1626. doi: 10.3390/cancers13071626. Cancers (Basel). 2021. PMID: 33915703 Free PMC article.
-
In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses.Nat Commun. 2022 Nov 1;13(1):6534. doi: 10.1038/s41467-022-33831-7. Nat Commun. 2022. PMID: 36319625 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous